One of China’s largest generics giants, CSPC Pharmaceutical Group Limited, has initiated its first bolt-on acquisition of 2022, drawing attention to potential merger and acquisition activity among domestic drug makers that could become a key theme to watch in the Year of the Tiger.
Hong Kong-listed CSPC announced the takeover of 51% of Guangzhou Recomgen Biotech through a wholly-owned partnership firm, according to a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?